{Update from Sam} Last week, I could hardly contain my frustration with the FDA’s inexplicable approval of a controversial medication for the treatment of Alzheimer’s Disease (AD). Aducanumab, the new drug in question, is a monoclonal antibody engineered to attack the amyloid plaques in the brains of AD patients, the bio-plausible hypothesis being that removal of […]
